Gilead second-quarter sales rise 8%, beating Wall Street estimates

Gilead reported an 8% increase in second-quarter sales, surpassing Wall Street estimates. Similarly, Amgen saw its second-quarter sales rise by 9%, with profits also exceeding Street views. Both pharmaceutical companies outperformed financial expectations during this period, demonstrating growth in their respective revenue streams. These results indicate a positive trend for both Gilead and Amgen as they beat the projections set by analysts for the second quarter of the current fiscal year.